SCHEMBL10243399

SCHEMBL10243399

CCN(CCNC(=O)OC)Cc1ccco1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
ALOX5 P09917 1/20 0.41
ALDH1A1 P00352 4/20 0.41
GAA P10253 3/20 0.41
MAPT P10636 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
POLB P06746 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4E B2RXH2 1/20 0.40
RAD52 P43351 1/20 0.40
RAB9A P51151 1/20 0.40
UBE2I P63279 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
CYP3A4 P08684 1/20 0.40
EPHX2 P34913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243447 0.78 APP (0.54) GAAKDM4E
SCHEMBL4541824 0.77 SIRT2 (0.49) GAAMAPT
SCHEMBL10243194 0.76 TRPM8 (0.44) RIPK1TRPM8ALDH1A1GAAMAPT
SCHEMBL11455443 0.75 HTR4 (0.73) ALDH1A1CYP1A2CYP2D6KDM4ERAB9A
SCHEMBL2806112 0.74 HTT (0.50) RIPK1TRPM8ALOX5ALDH1A1MAPT
SCHEMBL13037027 0.74 EPHX1 (0.50) ALDH1A1CYP1A2CYP2D6POLBKDM4E
SCHEMBL1642904 0.74 HTT (0.50) RIPK1TRPM8ALOX5ALDH1A1MAPT
SCHEMBL10243105 0.74 APP (0.61)
SCHEMBL18769149 0.74 HSD17B10 (0.67) ALDH1A1GAAMAPTPOLBHSD17B10
SCHEMBL10243111 0.73 POLB (0.46) ALDH1A1GAAMAPTCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 RIPK1 3301/4885TRPM8 4534/4885ALOX5 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.